Leiden, The Netherlands, November 26, 2008. Biotech company Pharming Group NV ("Pharming") (NYSE Euronext: PHARM) announced today that its wholly owned subsidiary DNage has successfully completed a Phase I trial, in healthy human volunteers, to evaluate the pharmacokinetics and tolerability of Prodarsan®.
